Miami, FL – October 21, 2019 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, reports on China Infrastructure Construction Corp. (OTC Pink: CHNC).

China Infrastructure Construction Corp. offers concierge medicine through its membership-based model in the Houston Metro area, Texas. The company is based in Houston, Texas.

Average daily volume for CHNC 24 million shares. Today’s news has caused the volume to increase to over 24 million shares in the morning hours of trading.

China Infrastructure Construction Corp.  Press Release:

HOUSTON, TX, Oct. 21, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – China Infrastructure Construction Corp. (CHNC) www.chnc-hdh.com is pleased to announce its acquisition of Precision Research Institute, LLC (PRI).

PRI is a Multi-Therapeutic, Dedicated Research Unit based in Houston, Texas. PRI brings multi-million-dollar contracts with the largest pharmaceutical companies in the world–like Abbvie, Samumed, Gilead, Intercept, Shire Pharmaceuticals, and more. President & CEO Elizabeth Hernandez says, “This acquisition of PRI, our second in the past year, now puts CHNC in the unique position of conducting its own clinical research trials. Which holds an important value the to the future of Medicine. CHNC is now in position to be the leader in the arena of Medical Clinical Trials. CHNC is in the process of becoming its very own Contract Research Organization (CRO) in the Industry. 

The looking forward to developing the future of Pharmaceutical, Biotechnology, and Pharmacovigilance Clinical Trials. PRI has Phase I, II, and III clinical trial capabilities–a rare feat. PRI’s facility is 4500 sq. ft. and currently has ongoing Phase II, III clinical trials, along with observational studies. Their fifteen active multi-million-dollar contracts is a great head start for CHNC. We look forward to expanding quickly!”

The acquisition, which has been approved by the board of directors, is subject to certain closing conditions, including OTC approval, approval by the stockholders of China Infrastructure Construction Corp. (CHNC), minimum cash balance of CHNC at closing, and other customary closing conditions.

About China Infrastructure Construction Corp. (CHNC)

Hippocrates Direct Healthcare, Inc. is a wholly owned subsidiary of CHNC, maintains a medical office, and also does clinical research for pharmaceutical companies. Hippocrates began with its membership-based model and now provides stem cell and clinical research services.

Hippocrates Direct Healthcare, Inc. is a wholly-owned subsidiary of China Infrastructure (CHNC). China Infrastructure’s common stock trades on the OTC Markets under the ticker symbol “CHNC.”

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “projects,” “intends,” and similar phrases. Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company’s control.

Hippocrates Direct Healthcare™ and the Hippocrates Direct Healthcare™ logo are all trademarks or registered trademarks of Hippocrates Direct Healthcare™, Inc.

CONTACTS:

Investors:
Hippocrates Direct Healthcare™, Inc.
Elizabeth@chnc-hdh.com
832-606-7500

Media:
elizabeth@chnc-hdh.com

About EmergingGrowth.com

EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies.  Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization.  We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth.  Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community.  Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information may include certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  EmergingGrowth.com, or its associates may have a position either long or short in any company mentioned herein. Please read our full disclosure, which can be found here, http://emerginggrowth.com/disclosure/. Please consult an investment professional before investing in anything viewed within this article or any other portion of EmergingGrowth.com. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.

Add a Comment to this Post

comments